Tests between the combination groups versus dabrafenib and trametinib combination were not statistically significant (dabrafenib and trametinib versus TMZ, p = 0.92, Mela14; dabrafenib and trametinib versus dabrafenib, trametinib, and TMZ, p = 0.10, p = 0.58, p = 0.09 Mela11, Mela14, Mela16, respectively; and dabrafenib and trametinib versus dabrafenib, trametinib, and TMZ salvage, p = 0.93, p = 0.80, p = 0.07 Mela11, Mela14, Mela16, respectively), with the exception of dabrafenib and trametinib versus TMZ (p < 0.05) for both Mela11 and Mela16. With the exception of Mela14 (TMZ versus DTT, p = 0.52; TMZ versus DTT salvage, p = 0.37), pairwise comparisons of DTT treatment ± salvage versus TMZ were all statistically significant (p < 0.05). Statistical analyses between DTT and DTT salvage were not statistically significant (p = 0.05, p = 0.49, p = 0.6 Mela11, Mela14, Mela16, respectively). (D-F) Change in percent body weight loss was calculated per mouse. The y-axis is change in body weight measured from baseline (day 1) ± SEM.
Supplementary Figure 4: Early treatment effects of triple therapy indicate pRb as a biomarker for response to therapy. (A)
Six mice were dosed, as previously described, with the indicated treatments for one week and protein lysates were extracted from snap frozen tumors collected after treatment. Immunoblotting using the antibodies indicated were repeated in triplicates using all mice, representative blots are shown. (B) Graphical representation of the relative intensities of the indicated antibodies normalized to beta actin control ± standard deviation. Statistically analysis is compared between no treatment and treated samples using a 2-sample t-test. The data used for this analysis were the raw mean values. 99 Growth inhibition rates were calculated at the end of the experiment on BRAF mutant PDTX tumor nodules in athymic nude mice treated with dabrafenib/trametinib, palbociclib, or all three in combination. a, Mean growth inhibition rate = growth rate of treated group/growth rate of untreated group b, Growth inhibition rate of dabrafenib/trametinib × growth rate of palbociclib. c, Growth inhibition rate of combined treatment on dabrafenib/trametinib and palbociclib treatments. d, Calculated by dividing the expected growth inhibition rate by the observed growth inhibition rate. An index >1.1 indicates synergistic effect, between 0.9 and 1.1 indicates additive effect, and <0.9 indicated less than additive effect. e, p-values were calculated using the Wilcoxon rank sum test, where palbociclib and triple therapy are both compared to dabrafenib/trametinib combination while the dabrafenib/ trametinib combination is compare to control treatment. MGI, mean growth inhibition. Mice were treated until study completion with indicated dosing and schedules. a, po, oral gavage; b, qd, everyday.
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